Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Current and Projected Market Size of the Locally Advanced Pancreatic Cancer Market Through 2034?
The market for locally advanced pancreatic cancer has experienced significant expansion in the past few years. It is projected to escalate from $0.95 billion in 2024 to $1.05 billion in 2025, boasting a compound annual growth rate (CAGR) of 10.9%. Factors contributing to the growth during the historic period include heightened awareness of pancreatic cancer, improved chemotherapy treatment plans, an uptick in the use of targeted therapies, an increase in pancreatic cancer incidence rates, the creation of more effective combination treatment protocols, and greater options for supportive care.
The market size of locally advanced pancreatic cancer is set to experience a significant spike in growth in the coming years, blooming to a market value of $1.57 billion by 2029 with a CAGR of 10.5%. This surge within the forecast period can be associated with the rising awareness towards pancreatic cancer, refinement of chemotherapy courses, the increased usage of targeted therapies, escalation in pancreatic cancer occurrences, the progression of combination treatment plans, and the improvement of supportive care alternatives. The forecast period will also witness vital trends such as breakthroughs in immunotherapy, the establishment of targeted therapies, enhancement in precision radiation methodologies, betterment in diagnostic imaging, the adoption of non-invasive surgical techniques, the inclusion of artificial intelligence in devising treatment plans, and advancements in combination therapy.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp
What Are the Primary Drivers Supporting the Market Growth of the Locally Advanced Pancreatic Cancer Market?
The growth of the market for locally advanced pancreatic cancer is expected to be propelled by the rising tobacco usage. Tobacco – a plant utilized in products such as cigars and cigarettes – contains nicotine, an addictive substance proven to cause severe health problems like cancer and cardiovascular disease. Factors like easy accessibility, affordability, promotion of tobacco products, social acceptance in certain areas, and smoking due to stress are contributing to the increased use of tobacco. This increase is directly related to the significant risk it poses for developing locally advanced pancreatic cancer due to its contribution to the heightened incidence of pancreatic malignancies. The US-based non-profit organization, Global Action to End Smoking, reported in January 2024 that approximately 62.9 million U.S. adults used tobacco in 2022, giving the U.S. a global ranking of 4th and 1st in the Americas. Furthermore, about 11.5% of U.S. adults (28.3 million) were cigarette smokers, with a higher proportion of males (13.1%) than females (10.1%) indulging in smoking. Therefore, the surge in tobacco usage is fueling the expansion of the locally advanced pancreatic cancer market.
Which Primary Segments of the Locally Advanced Pancreatic Cancer Market Are Driving Growth and Industry Transformations?
The locally advanced pancreatic cancer market covered in this report is segmented –
1) By Therapy: Chemotherapy, Immunotherapy, Radiation Therapy, Surgery
2) By Route Of Administration: Oral, Injectables, Other Route Of Administrations
3) By End-User: Hospital, Specialty Clinics, Research Institutions, Other End-Users
Subsegments:
1) By Chemotherapy: Gemcitabine-based Chemotherapy, FOLFIRINOX Chemotherapy
2) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines
3) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy (SBRT)
4) By Surgery: Pancreaticoduodenectomy (Whipple Procedure), Distal Pancreatectomy, Total Pancreatectomy
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21214&type=smp
Which Regions Are Key Players in the Growth of the What Are the Primary Drivers Supporting the Market Growth of the Locally Advanced Pancreatic Cancer Market? Market?
North America was the largest region in the locally advanced pancreatic cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Most Significant Market Trends in the Locally Advanced Pancreatic Cancer Market?
Key players in the locally advanced pancreatic cancer market are concentrating on the creation of novel products such as orphan drugs, with the aim of expanding treatment choices, improving patient outcomes, and meeting the unresolved healthcare needs related to this serious condition. Orphan drugs, designed to address rare diseases impacting a small populace, receive support from regulatory bodies through tax cuts and assured market exclusivity to encourage their creation. For example, in January 2025, Actuate Therapeutics Inc., a biopharmaceutical firm based in the United States, reported that Elraglusib, its new GSK-3ß inhibitor, had been granted Orphan Drug Designation by both the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) for the treatment of pancreatic ductal adenocarcinoma (PDAC) – a potential type of locally advanced pancreatic cancer. This designation underscores its potential to address a crucial gap in the treatment of this extreme form of cancer, primarily following promising results from Phase 2 trials demonstrating significant clinical progress and anti-cancer effects in patients with metastatic PDAC.
View the full report here:
What Parameters Are Used to Define the Locally Advanced Pancreatic Cancer Market?
Locally advanced pancreatic cancer (LAPC) refers to a stage of pancreatic cancer where the tumor is confined to the pancreas and surrounding tissues but has not spread to distant organs. This cancer is usually not suitable for surgical removal due to its involvement with vital blood vessels or nearby structures.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21214
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model